AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03049891 — intervention group
Intervention type: OTHER
Intervention: Data abstraction
Description: The investigators will abstract clinical data from down-referral sites and from NHLS to determine whether children made it to their down-referral sites or whether children are in care at a different facility.
Study NCT03049891 — intervention group
Intervention type: OTHER
Intervention: Tracing questionnaire
Description: The investigators will attempt to contact and visit caregivers of children who are determined to be LTF from DNH or from down-referral sites. If located and after providing consent, caregivers will be administered a tracing questionnaire, or a verbal autopsy if their child has died.
Study NCT03811743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coordination
Description: This component adds four additional strategies: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment. This innovative approach will seek to employ components of motivation and communication theories to increase self-monitoring, positive communication, problem solving, and social support to increase healthy physical activity and eating behaviors to increase the effectiveness of the weight loss programs beyond gains observed in matched controls.~Essentials (adults), with four additional components: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment
Study NCT03049891 — intervention group
Intervention type: OTHER
Intervention: Tier.net
Description: For all children who started ART at DNH between 2004 and 2013, the investigators will abstract data on these children from the electronic medical system in South Africa called Tier.net.
Study NCT02892357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment group
Description: Jianpi Qinghua granules:twice a day,1 bag a time;10mg omeprazole and 10mg sham ,once a day,all for 4 weeks.
Study NCT02892357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: sham Jianpi Qinghua granules:twice a day,1 bag a time; 20mg omeprazole once a day ,all for 4 weeks.
Study NCT00917553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxycycline monohydrate
Description: 50 mg
Study NCT00917553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cellulose Placebo Capsule
Study NCT04239807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group 1 GALILEO WBV
Description: 3 month home based WBV training
Study NCT02762786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: musical training
Description: The subjects in the experimental group will receive weekly one-hour lessons on musical training for 12 weeks, conducted by the Music Children Foundation.
Study NCT04239807 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Group 1 GALILEO WBV
Description: 3 month home based WBV training
Study NCT04239807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2 Control
Description: Training on the floor without WBV
Study NCT04239807 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group 2 Control
Description: Training on the floor without WBV
Study NCT05316831 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV13
Description: Pneumococcal polysaccharides conjugated to CRM197 carrier protein
Study NCT05316831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPSV23
Description: Pneumococcal polysaccharides
Study NCT01654224 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Inactivated Influenza Vaccine
Description: 0.5 ml HDIV consisting of 180 mcg (60 mcg each strain) of influenza virus hemagglutinin
Study NCT01654224 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Inactivated Influenza Vaccine
Description: 0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg each strain) of influenza virus hemagglutinin
Study NCT01594424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 8mg/kg on Days 0, 15, 30, 45, 75, 105, 119, 135, 149, and 180
Study NCT01594424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin
Description: All HS who meet criteria for desensitization will receive IVIG 10% (2.0 g/kg \[maximum 140 g per dose\] on days 1 and 30).
Study NCT00754273 — intervention group
Intervention type: OTHER
Intervention: etest susceptability testing
Description: E-test methodology is performed on all MRSA samples using standardized inoculum (0.5 McFarland) for Tigecycline, Vancomycin, Teicoplanin, and Linezolid. E test is performed using heavy inoculum for Vancomycin and Teicoplanin (2.0 McFarland).
Study NCT00453635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel at the dose of 75mg/m\^2 IV on day 1 every 3 weeks for 6 consecutive cycles
Study NCT00453635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin at the dose of 5 AUC IV on day 1 every 3 weeks for 6 consecutive cycles
Study NCT00453635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin 8 mg/Kg on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles, IV, every 3 weeks
Study NCT00453635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine at the dose of 60mg/m\^2 per os,weekly
Study NCT03758196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation instruments
Description: Renal Sympathetic Denervation from the adventitia of renal artery
Study NCT02299284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Home-based Bimanual and Lower-limb Training in Young Children With Hemiplegia
Study NCT03161574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
Study NCT00932165 — intervention group
Intervention type: DRUG
Intervention: Exemestane
Description: Aromasin® Tablets 25mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  The usual adult dose is 25 mg of exemestane administered orally once daily after a meal.
Study NCT05115916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyChart Priming Message
Description: In addition to the standard FIT mailer protocol, we will send randomized participants a message via their personal health portal. Patients receive the primer approximately 1-2 weeks prior to arrival of the FIT kit, which informed patients about the incoming FIT Kit and instructed patients to complete and return the kit promptly.
Study NCT03537313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vagina douching
Description: Vaginal douches with 1000 ml of 1% povidone-iodine solution on the night before surgery and again on the morning of surgery
Study NCT03537313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vagina painting
Description: Vaginal painting of vagina stump after hysterectomy with 10% povidone-iodine solution 30 ml
Study NCT01650272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% MInoxidil milky lotion
Description: Patient receive 5% MInoxidil milky lotion (Butylene glycol solvent)
Study NCT01650272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Minoxidil solution
Description: Patient receive 5% Minoxidil solution (Propylene glycol solvent )
Study NCT04311463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine hydrochloride
Description: Paroxetine hydrochloride will be administered.
Study NCT04311463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAXIL (Paroxetine hydrochloride )
Description: PAXIL will be administered.
Study NCT01780753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Primaquine GPO® (Government Pharmaceutical Organization, Thailand) 0.5 mg/kg will be given once daily for 14 days.
Study NCT01112111 — intervention group
Intervention type: DRUG
Intervention: mode of gonadotropin administration
Description: Low dose step-up administration Step down administration sequential administration
Study NCT01599741 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose DSA (83% reduction compared to normal dose) with novel X-ray imaging technology.
Description: Digital Subtraction Angiography (DSA) of iliac artery with reduced dose settings (83% dose reduction expected) in combination with novel X-ray imaging technology.
Study NCT01599741 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Normal dose DSA with conventional X-ray imaging technology
Description: Digital Subtraction Angiography (DSA) of iliac artery with normal dose settings in combination with conventional X-ray imaging technology.
Study NCT04784468 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Case-control design, one single investigation
Study NCT01616173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: IV dexamethsone 8mg in 50mL (diluted in NS)
Study NCT02528682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MiHA-loaded PD-L-silenced DC Vaccination
Description: Eligible patients will receive one cycle of donor DC vaccination consisting of maximal 3 immunizations, given at 2 week intervals. PD-L1/L2-silenced, MiHA mRNA-electroporated donor DC will be infused intravenously (2.5x105/kg body weight).
Study NCT05740865 — intervention group
Intervention type: PROCEDURE
Intervention: open posterior instrumented thoracolumbar surgery
Description: Both group previously received open posterior instrumented thoracolumbar surgery in 4 centers
Study NCT01204762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegIFN
Description: Syringe, Subcutaneous, 180 μg, Once Weekly, 48 weeks
Study NCT01204762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegIFNα-2a
Description: Syringe, Subcutaneous 180 μg, Once Weekly, 48 Weeks
Study NCT01204762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN lambda
Description: Syringe, Subcutaneous, 180 µg, Once weekly, 48 weeks
Study NCT01204762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Tablet, Oral, 0.5 mg, Once daily, 12 weeks initial monotherapy followed by 48 weeks of combination therapy with PegIFN lambda
Study NCT04678791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Patients receive Nimotuzumab 400 mg each time, once a week, slow intravenous drip, for a total of 6 weeks.
Study NCT04678791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Patients receive 40 mg/m2, d1, 7 days as 1 treatment cycle, 6 treatment cycles in total
Study NCT04678791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients receive 40 mg/m2, d1, 7 days as 1 treatment cycle, 6 treatment cycles in total
Study NCT01616173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 8mg/2mL
Study NCT01616173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 2mL
Study NCT00166504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe (+) simvastatin
Description: simvastatin/ezetimibe 10/20 mg
Study NCT04678791 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External-beam radiation
Description: Patients undergo IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45 - 50.4 Gy; 1.8 - 2.0 Gy/f, 25 - 28 f.
Study NCT04678791 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External-beam radiation
Description: Patients undergo IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45 - 50.4 Gy; 1.8 - 2.0 Gy/f, 25 - 28 f.
Study NCT04678791 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: Patient undergo Brachytherapy with high dose rate, with a total dose of 30-40 Gy and a cumulative dose of 80 \~ 85 Gy at point A/HRCTV D90; if the tumor diameter is ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90.
Study NCT04678791 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Patient undergo Brachytherapy with high dose rate, with a total dose of 30-40 Gy and a cumulative dose of 80 \~ 85 Gy at point A/HRCTV D90; if the tumor diameter is ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90.
Study NCT03574402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avitinib Maleate
Description: 300mg orally (PO) twice daily (BID) on day 1-28.
Study NCT03574402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 40mg orally once a day, 28 days as one cycle.
Study NCT03574402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: 250mg PO QD on days 1-28. 28 days as one cycle.
Study NCT04205058 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard coffee
Description: One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
Study NCT04205058 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine-free coffee
Description: One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
Study NCT04205058 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Drinking water
Description: One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
Study NCT00079430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00079430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00079430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given intraperitoneally
Study NCT00079430 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT01598194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel 22-gauge Core Biopsy Needle + Standard Biopsy Needle
Description: Two passes performed with the standard 22-gauge or 25-gauge straight hollow core needle and two passes will be performed using the 22-gauge EchoTip® Procore™ needle. All passes will be taken from a single lesion and from the same endoscopic location.
Study NCT04568057 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIR Transcranial phototherapy device
Description: 1068 nm NIR helmet
Study NCT04568057 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Transcranial Device
Description: The placebo device looks like the active device.
Study NCT01103687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ENVA.01 (rAd26)
Description: 5 x 10\^10 virus particles (VP) vaccine delivered intramuscularly (IM)
Study NCT01103687 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: Placebo vaccine delivered IM
Study NCT03574402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-396
Description: 225mg PO QD on days 1-28. 28 days as one cycle.
Study NCT03574402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 30mg orally twice weekly, 28 days as one cycle.
Study NCT03574402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Maleate
Description: 400mg PO QD on days 1-28. 28 days as one cycle.
Study NCT03574402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3759
Description: 200mg PO BID on days 1-28. 28 days as one cycle.
Study NCT01427608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline + Olanzapine
Description: Olanzapine 15mg/day. Adjustment of dose to 5mg/day to a maximum of 20mg/day will be permitted if necessitated by significant side-effects or clinical worsening
Study NCT01427608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sertraline + Placebo
Description: Taper from current dose of olanzapine to placebo over 4 weeks. Continue placebo for remainder of 36 week study.
Study NCT05697523 — intervention group
Intervention type: OTHER
Intervention: Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test
Description: Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test
Study NCT01806571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT03574402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirotinib
Description: 60mg PO QD/40mg PO BID on days 1-28. 28 days as one cycle.
Study NCT00003799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00003799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT03620474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRI-724
Description: twice a week for 4 hours continuous intravenous administration of PRI-724
Study NCT02798016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma
Description: This Platelet-Rich Plasma will be taken from each patient and is going to be used in the treatment of atrophic acne scars
Study NCT02798016 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-Rich Plasma
Description: This Platelet-Rich Plasma will be taken from each patient and is going to be used in the treatment of atrophic acne scars
Study NCT02798016 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Micro-needling
Description: Micro-needling will be applied on the acne scars in one side of the face.
Study NCT02032004 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Precursor Cells (MPCs)
Description: Rexlemestrocel-L consists of human bone marrow-derived allogeneic MPCs isolated from bone mononuclear cells with anti-STRO-3 antibodies, expanded ex vivo, and cryopreserved
Study NCT02032004 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: The sham procedure will be staged to script and will not include actual cardiac mapping or delivery of rexlemestrocel-L.
Study NCT01958346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lingual Traction
Description: The tongue pulling maneuver consists of grasping the tongue with 4x4cm gauze and gently pulling the tongue out until resistance is met.
Study NCT01958346 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Standard of care fiberoptic intubation without any additional experimental maneuvers
Study NCT03574402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 400mg, iv gtt. on day 1,8,15. 21 days as one cycle.
Study NCT03574402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m\^2, iv gtt. Q3W. 21 days as one cycle.
Study NCT00003799 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study NCT00003799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT03574402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m\^2, iv gtt. Q3W on day1. 21 days as one cycle.
Study NCT03574402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg iv gtt. Q3W on day1. 21 days as one cycle.
Study NCT01958346 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Fiberoptic Intubation
Study NCT01958346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fiberoptic Intubation
Study NCT03072706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corin OPS™
Description: The OPS Dynamic Hip Analysis is a computer software package used to generate simulations of a total joint replacement from patient imaging. The dynamic simulation is used for operative planning, including implant selection, sizing and placement; and to create custom instruments or delivery specifications referencing the patient's anatomy and bio-mechanics. The simulation can also be used for the post-operative evaluation of joint performance.
Study NCT03072706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2D X-ray templating technology
Description: Standard care where hip replacement is planned using 2D X-ray templating software
Study NCT00391066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCR + Lumiliximab
Description: Dose, schedule, and duration specified in the protocol
Study NCT00391066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FCR
Description: Dose, schedule, and duration specified in protocol
Study NCT01806571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT01806571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03574402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1g/m\^2 iv gtt. on day1,8. 21 days as one cycle.